EntreMed Announces Robust Anticancer Activity for ENMD-2076 In Triple-negative Breast Cancer

EntreMed, Inc.

, a clinical-stage pharmaceutical company developing targeted therapeutics for the treatment of cancer, announced today the publication of favorable results of a preclinical study in breast cancer of its oral Aurora A/angiogenic kinase inhibitor, ENMD-2076.  (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) The article, entitled "Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models" reports evidence that ENMD-2076 exhibited robust anticancer activity against breast cancer cell lines lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and without HER2‑amplification: a particularly difficult to treat subtype termed "triple-negative" breast cancer (TNBC).  TNBC is associated with a shortened disease-free and overall survival at all stages of diagnosis when compared to other breast cancer subtypes.  Candidate predictive biomarkers were also identified which may be useful in selecting patients that are particularly sensitive to this compound, ENMD-2076, in the future.  In this study, a diverse panel of twenty-nine breast cancer cell lines representative of the clinically defined breast cancer subtypes were exposed to ENMD-2076 and the effects on proliferation, apoptosis, and cell cycle distribution were evaluated.  ENMD-2076 demonstrated more